Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$19.60 USD
+0.74 (3.92%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $19.42 -0.18 (-0.92%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Cullinan Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 19 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 19 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 191 | -145 | 87 | 60 | 22 |
Income After Depreciation & Amortization | -191 | 145 | -68 | -60 | -22 |
Non-Operating Income | 22 | 7 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -169 | 151 | -67 | -59 | -22 |
Income Taxes | -14 | 42 | 0 | 0 | 0 |
Minority Interest | -2 | -2 | -2 | -8 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -155 | 109 | -67 | -59 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -153 | 111 | -66 | -52 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -191 | 145 | -68 | -60 | -22 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -191 | 145 | -68 | -60 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 41.55 | 46.64 | 43.08 | 9.45 | NA |
Diluted EPS Before Non-Recurring Items | -3.69 | 2.38 | -1.52 | -5.48 | NA |
Diluted Net EPS (GAAP) | -3.69 | 2.38 | -1.52 | -5.48 | NA |
Fiscal Year end for Cullinan Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 50.03 | 42.99 | 45.49 | 45.24 | 37.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | -50.03 | -42.99 | -45.49 | -45.24 | -37.60 |
Non-Operating Income | 8.00 | 5.65 | 5.80 | 6.06 | 5.39 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -42.03 | -37.34 | -39.69 | -39.18 | -32.21 |
Income Taxes | 0.00 | 0.00 | -14.12 | 0.00 | 0.00 |
Minority Interest | 0.00 | -0.19 | -1.76 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -42.03 | -37.34 | -25.56 | -39.18 | -32.21 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -42.03 | -37.15 | -23.80 | -39.18 | -32.21 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 55.05 | 43.01 | 42.79 | 42.73 | 39.95 |
Diluted EPS Before Non-Recurring Items | -0.75 | -0.86 | -0.54 | -0.91 | -0.82 |
Diluted Net EPS (GAAP) | -0.75 | -0.86 | -0.54 | -0.91 | -0.82 |